Consideration the changes of renal function for renal cell carcinoma patients, administered the molecular target drugs: axitinib, sunitinib and sorafenib

Consideration the changes of renal function for renal cell carcinoma patients, administered the molecular target drugs: axitinib, sunitinib and sorafenib - Consideration the changes of renal function for renal cell carcinoma patients, administered the molecular target drugs

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019393

Enrollment

Registered

2015-10-19

Start date

2015-10-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal cell carcinoma

Interventions

A daily dose of the molecular target drug, axitinib is determined by eGFR (10mg on over 45, 6mg on low by 45). We evaluate the blood exam containing a renal function 1,2,4 and 12 weeks later from adm

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Renal cell carcinoma with target lesion

Exclusion criteria

Exclusion criteria: Renal cell carcinoma without target lesion

Design outcomes

Primary

Measure	Time frame
For renal cell carcinoma patients, we evaluate the blood exam containing a renal function 1,2,4 and 12 weeks later from administration of the molecular target drugs whose daily doses are determined by eGFR (axitinib 10mg, sorafenib 800mg, sunitinib 50mg on over 45), (axitinib 6mg, sorafenib 800mg, sunitinib 37.5mg on low by 45).	—

Secondary

Measure	Time frame
We consider a therapeutic effect by administering the molecular target drug that is axitinib, sunitinib or sorafenib. Therapeutic effect for target lesions is examined using CT. The time for measuring is before and 4, 12weeks later from administration. For the case with preoperative setting, PET is performed before and after administration.	—

Countries

Japan

Contacts

Public ContactHironori Betsunoh

Dokkyo Medical University Urology

hirobets@dokkyomed.ac.jp0282872162

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026